- Home
- ATXS vs CLDT Comparison
ATXS vs CLDT Comparison
Compare ATXS & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- CLDT
- Stock Information
- Founded
- ATXS 2008
- CLDT 2009
- Country
- ATXS United States
- CLDT United States
- Employees
- ATXS N/A
- CLDT N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- CLDT Real Estate Investment Trusts
- Sector
- ATXS Health Care
- CLDT Real Estate
- Exchange
- ATXS Nasdaq
- CLDT Nasdaq
- Market Cap
- ATXS 401.2M
- CLDT 351.7M
- IPO Year
- ATXS 2015
- CLDT 2010
- Fundamental
- Price
- ATXS $4.76
- CLDT $7.13
- Analyst Decision
- ATXS Strong Buy
- CLDT Strong Buy
- Analyst Count
- ATXS 7
- CLDT 2
- Target Price
- ATXS $32.43
- CLDT $10.75
- AVG Volume (30 Days)
- ATXS 625.9K
- CLDT 271.2K
- Earning Date
- ATXS 05-13-2025
- CLDT 05-06-2025
- Dividend Yield
- ATXS N/A
- CLDT 5.05%
- EPS Growth
- ATXS N/A
- CLDT N/A
- EPS
- ATXS N/A
- CLDT 0.06
- Revenue
- ATXS N/A
- CLDT $316,297,000.00
- Revenue This Year
- ATXS N/A
- CLDT N/A
- Revenue Next Year
- ATXS N/A
- CLDT $13.03
- P/E Ratio
- ATXS N/A
- CLDT $123.12
- Revenue Growth
- ATXS N/A
- CLDT 1.79
- 52 Week Low
- ATXS $3.56
- CLDT $5.83
- 52 Week High
- ATXS $12.92
- CLDT $10.00
- Technical
- Relative Strength Index (RSI)
- ATXS 54.89
- CLDT 52.36
- Support Level
- ATXS $3.83
- CLDT $7.08
- Resistance Level
- ATXS $4.98
- CLDT $7.26
- Average True Range (ATR)
- ATXS 0.45
- CLDT 0.13
- MACD
- ATXS 0.11
- CLDT 0.01
- Stochastic Oscillator
- ATXS 82.93
- CLDT 53.03
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About CLDT Chatham Lodging Trust (REIT) of Beneficial Interest
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.